Obesity
Conditions
Brief summary
This controlled clinical trial aims to compare the effects of an online program that includes exercise guided by the FITT-VP principle and dietary advice, conducted by fitness coaches, in children and adolescents with obesity with a control group that will be enrolled in conventional in-clinic nutrition and exercise advice. All participants will be monitored for 8 months during the active intervention, and followed by 16 months of observation. The study will evaluate the following parameters between groups: BMI, anthropometry, blood biochemistry panel (ALT/AST, lipids, uric acid, HOMA-IR, HbA1c), food frequency questionaire, household survey, satisfaction survey, and adverse events.
Interventions
1. Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4\~6 peers. 2. Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1). 3. Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance.
Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Simple obesity: Body mass index (BMI) between +2SD and +3SD of the reference range: based on the "Standard Deviation Curve of BMI for Children 0-18 Years of Age in China", which was developed by the Physical Development Survey of Children in Nine Provinces/Cities in 2005; 2. Not participating in other weight management programs currently or in the 3 months prior to the study; 3. Accepts to participate and signs informed consent.
Exclusion criteria
1. Currently taking or planning to take medications or interventions that affect body weight during the study period (32 weeks) 2. Obesity caused by other medical conditions. For example, hypothalamic-pituitary disease, hypothyroidism, growth hormone deficiency, Cushing's syndrome, obesity-related syndromes. 3. Comorbidity with other chronic diseases. E.g. psychiatric diseases, respiratory diseases, gastrointestinal diseases, rheumatic diseases, hepatic and renal insufficiency, chronic infectious diseases; 4. Presence of abnormal laboratory values at the time of screening indicating a clinically significant underlying disease or condition that may prevent the subject from participating in the study; or presence of abnormalities in the following laboratory tests: alanine aminotransferase (ALT) greater than 5 times the upper limit of normal, serum creatinine (Scr) greater than 1.5 times the upper limit of normal. 5. Contraindications to physical exercise or exercise-related risks. For example, history of asthma, history of hypoglycemia/diabetes, history of heart disease, history of cardiovascular disease, fracture/surgery/planned surgery within the last 1 year, psychomotor retardation, motor system defects/disabilities, previous history of exercise intolerance;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BMI | 16, 32, 52, 104 weeks | Reduction in body mass index (the body mass \[kg\] divided by the square of the body height \[m\]) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dietary habits | 16, 32, 52, 104 weeks | Change in dietary habits assessed by food frequency questionaire (2015 CHNS) |
| AE | 16, 32, 52, 104 weeks | Adverse events during active intervention by questionaire and healthcare records according to local regulations (PMID: 34327433) |
| Uric acid | 16, 32 weeks | Reduction in serum uric acid levels |
| Tch | 16, 32 weeks | Reduction in serum total cholesterol |
| LDL-c | 16, 32 weeks | Reduction in serum low density lipoprotein cholesterol |
| HbA1c | 16, 32 weeks | Reduction in glycated hemoglobin |
| HOMA-IR | 16, 32 weeks | Reduction in this surrogate marker of beta-cell function and insulin resistance (IR) from basal (fasting) glucose and concentrations. |
Countries
China